



Perceptronix
Early diagnosis, better outcomes™

PRESS RELEASE

For immediate release

PERCEPTRONIX RECEIVES US FOOD AND DRUG ADMINISTRATION MEDICAL DEVICE LISTING AND C€ MARK FOR CLEAR2C™

VANCOUVER, CANADA (April 4, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been issued a Medical Device Listing from the US Food and Drug Administration (FDA) and C€ Mark for its Clear2C™ Quantitative DNA Staining Kit. Perceptronix will now begin marketing and selling this product to all laboratories requiring consistent quantitative absorbance microscopy staining in the United States, Canada, and the European Union (EU) .

Clear2C™ is a patent pending Quantitative DNA Staining Kit designed to deliver convenient, repeatable and reliable DNA staining for absorbance microscopy. While optimized for DNA quantification with the Perceptronix ClearCyte™ Quantitative Cytology System, it can also be effectively used with other cytometry platforms.

“Considerable development work has gone into optimizing the staining formulation and protocol of Clear2C™ for DNA stain linearity, specificity and repeatability. We believe this kit also provides quality and convenience at a cost effective price for large slide volume customers,” said Dr. Bojana Turic, Vice President and Director of Clinical and Regulatory Affairs for Perceptronix.

Perceptronix recently announced the opening of its Quantitative Cytology Laboratory in Vancouver, British Columbia, offering **ClearCyte™** tests. ClearCyte™ is an automated microscopy imaging system used to measure DNA properties in cell samples of different tissues such as breast, bladder, mouth, lung etc. Combined with expert interactive review of cells, ClearCyte™ test results may provide clinicians with valuable information related to the clinical diagnosis and prognosis of cancer. Quantitative staining of DNA using the Clear2C™ Quantitative DNA Staining Kit is a central element of the ClearCyte™ test.

Notes to Editors

“Quantitative Cytology” is the precise measurement of cell features. This technique permits the detection of very extensive changes to the DNA of cells (also called “DNA ploidy” or “Gross Genomic Aberrations”), which are often signatures of cancer cells. The ClearCyte™ technology combines fully automated imaging and measurement of cells on a microscope slide with the ability to interactively review any or all of the cells in the context of their measurements for accurate specimen assessment. When added to other clinical information, these cell measurements may provide physicians with important diagnostic and prognostic information about their patient. In order for such measurements to be valid, the DNA must be stained precisely. The Clear2C™ Quantitative DNA Staining Kit provides this accuracy in a convenient and cost effective package.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with



the BC Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs. Perceptronix's goal is to develop and commercialize a suite of technologies and services to approach cancer diagnosis comprehensively: early detection, localization, diagnosis and follow-up. The first of Perceptronix's technologies to receive regulatory approval is the ClearCyte™ Quantitative Cytology System and its associated Clear2C™ Quantitative DNA Staining Kit which assist physicians with clinical diagnosis and prognosis of cancer.

The ClearCyte™ test (with a Health Canada license and CE Mark approval), is used to measure "DNA Ploidy" (see above) and is now offered by the Perceptronix Quantitative Cytology Laboratory in Vancouver.

Clear2C™ has a Health Canada license, CE Mark and US Food & Drug Administration Medical Device Listing and is marketed in Canada, EU and the USA.

The Perceptronix product pipeline also includes ClearSign™, a sputum based early lung cancer detection test, ClearVu™ and ClearVu™ Elite simultaneous and spectral fluorescence/white light endoscopy systems, and ClearPath™, an aid to definitive diagnosis of biopsy sections.

Contact:

Susan Grose
Corporate Secretary
Perceptronix Medical Inc.
Ste. 400, 555 West 8th Avenue
Vancouver, Canada V5Z 1C6
Phone: (604) 707 – 9037
info@perceptronix.com